Development of an immunofluorescent AR-V7 circulating tumor cell assay - A blood-based test for men with metastatic prostate cancer.

导出 LinkOut

翻译打印收藏纠错

作者： David,Lu ^[1] ; Rachel,Krupa ^[2] ; Melissa,Harvey ^[1] ; Ryon P,Graf ^[1] ; Nicole,Schreiber ^[1] ; Ethan,Barnett ^[3] ; Emily,Carbone ^[4] ; Adam,Jendrisak ^[3] ; Audrey,Gill ^[3] ; Sarah,Orr ^[1] ; Howard I,Scher ^[1] ; Joseph D,Schonhoft ^[1]

作者单位： Epic Sciences, San Diego, California - USA. ^[1] Exact Sciences, Madison, Wisconsin - USA. ^[2] Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York - USA. ^[3] Prostate Cancer Clinical Trials Consortium, New York, New York - USA. ^[4] Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York - USA. ^[5] Department of Medicine, Weill Cornell Medical College, New York, New York - USA. ^[6]

关键词 AR-V7 Castration-resistant prostate cancer Circulating tumor cells (CTCs)Predictive biomarkers

DOI 10.33393/jcb.2020.2163

PMID 33717359

发布时间 2022-04-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Journal of circulating biomarkers

13-19页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Development of an immunofluorescent AR-V7 circulating tumor cell assay - A blood-based test for men with metastatic prostate cancer.

Journal of circulating biomarkers

相似文献

Journal of circulating biomarkers

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Development of an immunofluorescent AR-V7 circulating tumor cell assay - A blood-based test for men with metastatic prostate cancer.

Journal of circulating biomarkers

相似文献

Journal of circulating biomarkers

相关期刊

检索历史清除